Univest
Univest
  • Markets

Shilpa Medicare Share Price Target 2026 Analyst Forecast Bull and Bear Case

  • June 30, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Shilpa Medicare Share Price Target 2026

Shilpa Medicare CMP Rs 590. 52W High Rs 599 | Low Rs 260. Mcap Rs 11,178 Cr. 12M Target Rs 660. PE: 45.94.

The Shilpa Medicare share price target, currently trading near its 52-week high of Rs 599, stands at Rs 660 for 2026, implying approximately 12% upside from the current market price of Rs 590. The stock trades at a price-to-earnings ratio of 45.94x, indicating balanced growth and value characteristics, with a market capitalisation of Rs 11,178 Cr. Investors tracking the pharmaceuticals segment are closely watching Shilpa Medicare as an emerging opportunity given its 52-week range of Rs 260 to Rs 599. This analysis covers the bull case, bear case, and key catalysts that will define the Shilpa Medicare share price target trajectory through 2026.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Shilpa Medicare Company Overview and Key Metrics
  • Why Is the Shilpa Medicare share price target Set at Rs 660 for 2026
    • FY27 Earnings Delivery and Revenue Acceleration
    • Domestic Formulations Growth and NLEM Coverage
    • USFDA and Export Approvals Pipeline
    • RBI Rate Cut Cycle and Lower Cost of Capital
    • Union Budget 2026 and Policy Tailwinds
  • Shilpa Medicare Share Price Target Short Term, 12 Month and Long Term
    • Short Term Shilpa Medicare Share Price Target: 3 to 6 Months
    • 12 Month Shilpa Medicare Share Price Target 2026
    • Long Term Shilpa Medicare Share Price Target: FY27 to FY28
  • Bull Case and Bear Case for Shilpa Medicare Share Price Target
    • Bull Case: Rs 760
    • Bear Case: Rs 530
  • Key Risks to the Shilpa Medicare Share Price Target 2026
    • Macro Headwind from Global Slowdown and US Tariff Policy
    • Valuation Risk and Earnings Miss Scenario
    • Competitive Pressure in the Pharmaceuticals Segment
    • FII Selling and Broader Market Volatility
  • How to Invest in Shilpa Medicare Stock
  • Conclusion
  • FAQs on Shilpa Medicare Share Price Target 2026
    • What is the Shilpa Medicare share price target for 2026?
    • Is Shilpa Medicare a good stock to buy right now?
    • What is Shilpa Medicare’s 52-week high and low?
    • What is the market cap of Shilpa Medicare?
    • What are the key risks to the Shilpa Medicare share price target?
    • What is the bull case target for Shilpa Medicare in 2026?
    • Where can I track Shilpa Medicare share price live?
    • How do I invest in Shilpa Medicare stock?

Shilpa Medicare Company Overview and Key Metrics

Shilpa Medicare Details
NSE Symbol SHILPAMED
Sector Pharmaceuticals
CMP (Rs) 590
52W High (Rs) 599
52W Low (Rs) 260
Market Cap (Rs Cr) 11,178 Cr
P/E Ratio 45.94
12M Target (Rs) 660
Bull Case (Rs) 760
Bear Case (Rs) 530

Shilpa Medicare is a pharmaceuticals company listed on the National Stock Exchange (NSE: SHILPAMED). With a market capitalisation of Rs 11,178 Cr, the company occupies a defined position in the Indian pharmaceuticals landscape. The stock has traded in a wide range over the past 12 months, touching a high of Rs 599 and a low of Rs 260, before arriving at its current level of Rs 590. Uniresearch analysts project a 12-month Shilpa Medicare share price target of Rs 660, with a bull case of Rs 760 and a bear case of Rs 530.

Why Is the Shilpa Medicare share price target Set at Rs 660 for 2026

FY27 Earnings Delivery and Revenue Acceleration

The Shilpa Medicare share price target of Rs 660 is anchored in expectations of FY27 earnings delivery. At a P/E of 45.94x on trailing earnings, the stock is priced for consistent execution. Consistent revenue growth and margin improvement in coming quarters can re-rate the stock towards the Rs 660 target.

Domestic Formulations Growth and NLEM Coverage

India’s pharma market is expanding at 10-12% annually driven by rising health awareness and increasing prescription volumes. Companies with a strong domestic branded generic presence are well-positioned to capture this structural demand growth.

USFDA and Export Approvals Pipeline

Pharma companies that successfully navigate USFDA inspections and build a credible ANDA pipeline can see significant margin expansion through regulated market sales. Export realizations are typically three to five times domestic pricing.

RBI Rate Cut Cycle and Lower Cost of Capital

The Reserve Bank of India has shifted to an accommodative monetary policy stance, with rate cuts reducing borrowing costs across the economy. For Shilpa Medicare, lower interest rates translate to reduced finance costs and potentially higher consumer demand in its end markets, creating a favourable backdrop for the Shilpa Medicare share price target to materialise by year-end.

Union Budget 2026 and Policy Tailwinds

The Union Budget 2026-27 has maintained strong capex allocation of Rs 11 lakh crore for infrastructure, directly benefiting sectors including pharmaceuticals. Tax rationalisation and sector-specific policy support create a constructive policy environment that supports the Shilpa Medicare share price target thesis through improved demand visibility.

Shilpa Medicare Share Price Target Short Term, 12 Month and Long Term

Short Term Shilpa Medicare Share Price Target: 3 to 6 Months

In the near term, the Shilpa Medicare share price target for the next 3 to 6 months is pegged at Rs 635, contingent on Q1 FY27 earnings meeting expectations and sustained buying interest in the pharmaceuticals segment. Technically, the stock needs to hold the Rs 273-286 zone for this short-term target to remain valid.

12 Month Shilpa Medicare Share Price Target 2026

Our 12-month Shilpa Medicare share price target is Rs 660. This target is based on the Uniresearch fundamental estimate, which factors in FY27 revenue growth, margin normalisation, and sector re-rating potential. The Rs 660 level represents approximately 12% upside from the current price of Rs 590.

Long Term Shilpa Medicare Share Price Target: FY27 to FY28

Over a 2 to 3 year horizon, the long-term Shilpa Medicare share price target is estimated between Rs 759 and Rs 891, assuming continued compounding in earnings, potential capacity expansions, and improved market positioning. Investors with a multi-year holding perspective may find the current CMP of Rs 590 an attractive accumulation level.

Bull Case and Bear Case for Shilpa Medicare Share Price Target

Bull Case: Rs 760

In the bull case scenario, Shilpa Medicare delivers above-estimate earnings growth driven by strong demand, margin expansion, and new business wins. If these catalysts materialise simultaneously, the Shilpa Medicare share price target could reach Rs 760, implying approximately 29% upside from the current market price.

Bear Case: Rs 530

The bear case of Rs 530 assumes earnings disappointment, sector-level de-rating, or broader market selloff driven by FII outflows. In this scenario, Shilpa Medicare could re-test support levels closer to its 52-week low of Rs 260, representing a downside risk investors should monitor.

Scenario Target Price (Rs) Upside/Downside from CMP Key Assumption
Bull Case 760 29% Strong earnings growth, sector re-rating
Base Case 660 12% Steady earnings, margin improvement
Bear Case 530 -10% Earnings miss, macro headwinds

Key Risks to the Shilpa Medicare Share Price Target 2026

Macro Headwind from Global Slowdown and US Tariff Policy

A sharper-than-expected global slowdown or escalation in US-China trade tensions could dampen demand across sectors. Shilpa Medicare faces indirect risk if its customers or supply chain partners are impacted by slower global growth, as this could translate to lower order volumes or pricing pressure.

Valuation Risk and Earnings Miss Scenario

If Shilpa Medicare reports quarterly earnings below analyst estimates or provides weak forward guidance, the stock could see significant de-rating. Elevated valuations in some segments leave limited margin for error, making execution risk a critical near-term concern.

Competitive Pressure in the Pharmaceuticals Segment

The pharmaceuticals space in India is increasingly competitive with both domestic players and global companies vying for market share. Price competition, product commoditisation, or loss of key client contracts could pressure Shilpa Medicare’s revenue trajectory.

FII Selling and Broader Market Volatility

Foreign Institutional Investor selling in Indian equities has historically led to broad-based price corrections even in fundamentally sound companies. Shilpa Medicare’s share price could face near-term pressure if FII sentiment turns risk-off due to global monetary policy changes.

How to Invest in Shilpa Medicare Stock

Step 1: Research and Fundamental Analysis. Before investing, thoroughly review Shilpa Medicare’s quarterly results, annual report, and management commentary. Focus on revenue growth trajectory, operating margin trends, and debt levels to assess whether the Shilpa Medicare share price target of Rs 660 is achievable.

Step 2: Use Stock Screeners for Live Data.

Check Shilpa Medicare Live Data on Univest Screener

Monitor key metrics including P/E, return on equity, and promoter holding changes. These ratios can confirm or challenge the Shilpa Medicare share price target thesis in real time.

Step 3: Define Your Entry Zone. The current CMP of Rs 590 is within the identified accumulation zone based on the 52-week low of Rs 260 and the Uniresearch target of Rs 660. Consider entering in tranches to average your cost over market fluctuations.

Step 4: Set Stop Loss and Risk Management Levels. Always define a stop-loss level before investing. A prudent stop-loss for Shilpa Medicare based on the current technical setup would be in the Rs 519 to Rs 543 range. Never risk more than 2-5% of your portfolio in any single position.

Step 5: Open a Zero-Brokerage Demat Account. To invest in Shilpa Medicare at zero brokerage, open your demat account with Univest, which combines SEBI-registered research with integrated trading. This allows you to act on the Shilpa Medicare share price target analysis without incurring unnecessary transaction costs.

Download the Univest iOS App or Univest Android App to track Shilpa Medicare live price and get daily stock recommendations.

Conclusion

The Shilpa Medicare share price target for 2026 is Rs 660, with a bull case of Rs 760 and a bear case of Rs 530, based on Uniresearch estimates as of 29 June 2026. At a CMP of Rs 590 with a 52-week range of Rs 260 to Rs 599, Shilpa Medicare presents a risk-reward opportunity that warrants monitoring. Investors should review Q1 FY27 results, track management commentary on guidance, and consult a SEBI-registered advisor before making investment decisions. The Shilpa Medicare share price target outlined here is for educational purposes only.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Shilpa Medicare Share Price Target 2026

What is the Shilpa Medicare share price target for 2026?

Ans. The Shilpa Medicare share price target for 2026, as per Uniresearch estimate, is Rs 660. This implies approximately 12% upside from the current market price of Rs 590.

Is Shilpa Medicare a good stock to buy right now?

Ans. Whether Shilpa Medicare is a good buy depends on your investment horizon, risk appetite, and portfolio allocation. The Uniresearch Shilpa Medicare share price target of Rs 660 implies meaningful upside, but investors must assess company fundamentals and market conditions before investing.

What is Shilpa Medicare’s 52-week high and low?

Ans. Shilpa Medicare’s 52-week high is Rs 599 and the 52-week low is Rs 260, as of 29 June 2026. The current price of Rs 590 represents a 127% gain from the 52-week low.

What is the market cap of Shilpa Medicare?

Ans. The market capitalisation of Shilpa Medicare is approximately Rs 11,178 Cr, as of 29 June 2026.

What are the key risks to the Shilpa Medicare share price target?

Ans. Key risks to the Shilpa Medicare share price target of Rs 660 include earnings disappointment, global macro headwinds, FII selling pressure, and competitive intensity in the pharmaceuticals sector. Any of these factors could delay or reduce the target realisation.

What is the bull case target for Shilpa Medicare in 2026?

Ans. In the bull case scenario, the Shilpa Medicare share price target could reach Rs 760, implying approximately 29% upside from the current level. This assumes stronger-than-expected earnings growth and sector re-rating.

Where can I track Shilpa Medicare share price live?

Ans. You can track Shilpa Medicare (NSE: SHILPAMED) live price, charts, and fundamental data on the Univest app or screener. The Univest platform provides real-time price data, analyst research, and portfolio tracking in one place.

How do I invest in Shilpa Medicare stock?

Ans. To invest in Shilpa Medicare, open a demat account with a SEBI-registered broker like Univest, which offers zero brokerage and integrated research. Search for the ticker SHILPAMED on NSE, review fundamentals using the Univest Screener, and invest based on your financial goals and risk profile.



News
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply